A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
06/04/2022at 10:23

Novo Nordisk loses two senior staff to alternative antibiotics firm

Swiss biotech company Micreos Pharmaceuticals, which is developing alternatives to antibiotics, has succeeded in its hunt for new upper-level employees for two newly established roles, poaching two employees from Novo Nordisk.
Carsten Edwards and Trine Ahlgreen | Photo: Micreos Pharmaceuticals / PR
by albert rønning-andersson, translated by daniel pedersen

Swiss Micreos Pharmaceuticals, which develops new biological therapies against unwanted bacteria within a number of indications, has announced the hires for two new positions, chief business officer and chief development officer, a company press release reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Daniel Karmann/AP/Ritzau Scanpix

    World's largest public-private antibiotic fund unveils first investments

    For subscribers

  • Mads Krogsgaard Thomsen, CEO at the Novo Nordisk Foundation. | Photo: Gregers Tycho/ERH

    Novo Nordisk Foundation's CEO warns antibiotic resistance will be world's second-biggest killer

    For subscribers

  • Photo: Novo Holdings / PR

    Novo's antibiotic fund participates in financing round of infectious diseases firm

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: Coloplast / Pr
Medtech

Coloplast is the world's most sustainable medtech firm in new analysis

Among 87 of the largest, publicly listed medtech companies, Coloplast has been deemed the very best on sustainability, according to a new international ranking. 

For subscribers

Foto: Stine Rasmussen/Ritzau Scanpix
Regulation

Denmark recommends three drugs

New treatments for arthritis, esophageal cancer, and depression will be available for Danish patients after the Danish Medicines Council has made new recommendations.

For subscribers

Foto: Novo Holdings / PR
Pharma & biotech

Novo Holdings invests in newly merged blood disease company

US-based Disc Medicine merges with another hematological firm, and the new combined company raises USD 53.3m from a consortium of investors.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Lead Data Architect

  • Head of Regulatory Affairs Danmark

  • Head of International Sales

  • Commercial Director

  • Application Manager

  • Application Manager

  • Principal Laboratory Technologist

  • Senior Regulatory Affairs Professional

  • Sr. Director, Drug Safety Physician

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Experienced Patent Counsel

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

See all jobs

Jobs

  • Lead Data Architect

  • Head of Regulatory Affairs Danmark

  • Head of International Sales

  • Commercial Director

  • Application Manager

  • Application Manager

  • Principal Laboratory Technologist

  • Senior Regulatory Affairs Professional

  • Sr. Director, Drug Safety Physician

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Experienced Patent Counsel

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge